By Gina Kolata
An experimental drug by Eli Lilly, called lepodisiran, has shown promising results in lowering Lp(a) levels, a particle linked to heart attack and stroke risk, by 94% with just one injection. While more studies are needed to confirm its effectiveness, this breakthrough could be significant for those with elevated Lp(a) levels, as existing treatments are limited.